Chicken pox vaccine is now offered in the sus

The Ministry of Health, through the National Immunization Program (PNI), starts to offer from this Month of September, throughout the public health network, the varicella vaccine (chickenpox) included in the tetra viral, which will also protect against measles, mumps and rubella. The new vaccine will make up the National Vaccination Calendar and will be offered exclusively to 15-month-old children who have already received the first dose of the triple viral vaccine. With the inclusion of the vaccine, the Ministry of Health estimates a reduction of 80% of hospitalizationsfor chickenpox (chickenpox).

“With just one injection, Brazil will be able to protect its children against four types of diseases. Today, we have data showing that almost nine thousand people are hospitalized each year by chickenpox and we have more than 100 deaths. In addition, it facilitates the work of professionals and brings savings, because it uses only a needle, a syringe, a single place of conservation”, said Minister Alexandre Padilha.

Withthe tetra viral, the SUS now offers 25 vaccines, 13 of them already available in the National Vaccination Calendar. R$ 127.3 million were invested to purchase 4.5 million doses per year. The population should report to the nearest health center to find out if thetetra viral vaccineis already available. This is because some municipalities are still asparading the routine to the new vaccine, because of the need for training professionals to administer the dose or the difficulty of distribution to the vaccine rooms in places of difficult access. It is expected that all 34,000 vaccination rooms distributed in Brazil will be offering the doses by the end of the month.

Thetetra viral vaccineis safe – it is 97% effective and rarely causes allergic reactions. There will be no vaccination campaign, asthe tetra viral vaccine willbe made available in the routine of public services in place of the second dose of the triple viral vaccine. The vaccine prevents complications, severe cases with hospitalization and possible death, in addition to the prevention, control and elimination of measles, mumps and rubella diseases.

PARTNERSHIPS– The national production ofthe tetra viral vaccineis the result of the partnership for technology transfer between the public laboratory Bio-Manguinhos and the British private laboratory GlaxoSmithKline (GSK). In technology transfer agreements signed by the Ministry of Health, production takes place through Partnerships for Productive Development (PDP), made with public laboratories. In this partnership, the laboratories of the private network are responsible for producing the active ingredient and transferring the technology. In return, the government guarantees exclusivity in the purchase of the drug for five years.

This is the seventh partnership between the private laboratory GSK and the public laboratory Bio-Manguinhos. Since 1980, laboratories have produced together poliomyelitis vaccines, Haemophilus influenzaetype b (Hib) – which causes meningitis and other bacterial infections – triple viral, rotavirus, dengue and pneumococcal conjugate, which protects against pneumonia and meningitis caused by pneumococcus.

In total, 35 PDPs are in place for the production of 33 products, 28 of which were medicines and four vaccines. The partnerships involve 37 laboratories, 12 public and 22 private, national and foreign.

Jeanne Kenney
 | Website

I’m a stylist trainer, a content creator, and an entrepreneur passion. Virgo sign and Pisces ascendant, I move easily between my dreams, the crazy world I want, and my feet on the ground to carry out my projects.

Leave a Reply

Your email address will not be published. Required fields are marked *